A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Martin Slusarczyk, PhD
Advertisement
Director, Zurich, with Simon-Kucher’s Life Sciences division
Articles by Martin Slusarczyk, PhD
The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.
The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.
Advertisement
Latest Updated Articles
Pharma Forecasting: Key Markets Investors Can’t IgnorePublished: December 13th 2024 | Updated:
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global InvestmentPublished: June 20th 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
Bob Mauch: Strengthening the Chain
3
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
4
mRNA Covid Vaccines Display Potential to Benefit Immunotherapy Cancer Drugs
5
